No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: A population approach

Therapeutic Drug Monitoring

Volumn 27, Issue 6, 2005, Pages 782-784

  Dailly, Eric ^a   Gagnieu, Marie Claude ^b   Allavena, Clotilde ^a   Raffi, François ^a   Jolliet, Pascale ^a  

^a HÔTEL DIEU   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Interaction; Lopinavir; Pharmacokinetics; Saquinavir

Indexed keywords

LOPINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE;

ADULT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SALVAGE THERAPY; ARTICLE; BAYES THEOREM; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLIC CLEARANCE RATE; MICROCAPSULE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; BAYES THEOREM; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; FEMALE; GELS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; PYRIMIDINONES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RITONAVIR; SAQUINAVIR;

EID: 33646844281     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000177663.89103.58     Document Type: Conference Paper

References (9)

1. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA. 2002;288:169-180.
2. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2004;75:310-323.
3. La Porte CJ, Wasmuth JC, Schneider K, et al. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS. 2003;17:1700-1702.
4. Stephan C, Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS. 2004;18:503-508.
5. Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4256-4262.
6. Dailly E, Raffi F, Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;813:353-358.
7. Urien S. Micropharm Population (MP2) - an interactive and user-friendly interfaced program for population pharmacokinetics. Proceedings of the second meeting of the Population Approach Group in Europe (PAGE), 13-14 June 1994, Greenford, London, UK.
8. Crommentuyn KM, Mulder JW, Mairuhu AT, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther. 2004;9:779-785.
9. Kurowski M, Sternfeld T, Hill A, et al. Comparative pharmacokinetics and short-term safety of twice daily (BID) Fortovase/Ritonavir and Invirase/Ritonavir. Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February, 2002, Seattle, WA.